ArQule stock: buy or sell?

ARQL stock price: $8.39 4.61% At close on September 20th, 2019

Updated on:
September 20th, 2019

1

Shares of ArQule closed today at $8.39 and climbed a super good 4.61%. Friday was the 4th climbing session in a row, soaring 7.78%.

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States.

Should I buy ArQule stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

Currently, ArQule stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is ArQule stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we gathered 5 ratings published for ARQL stock in the last 30 days.

The general sentiment of these ratings is bullish for ARQL stock, with 5 positive ratings.
Is ARQL a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-9-16HC Wainwrightn/aBuy
2019-6-19Royal Bank of Canadan/aOutperform
2019-6-14Roth Capitaln/aBuy
2019-5-2Royal Bank of Canadan/aBuy
2019-4-11Royal Bank of Canadan/aOutperform

ArQule stock analysis

Daily outlook

ArQule shares climbed 4.61% to $8.39 today.

ArQule climbed a super good 4.61% and closed at $8.39. ARQL is soaring again after a 8.29% correction from its last top on September/11 at $8.44. On May, SMA100d and SMA200d crossed up triggering a rise of 17.02%. Since price and SMA100d lines crossed down on September/9, ARQL fell $-0.93 per share (-9.98%).

ARQL stock chart (daily)

Weekly outlook

After sliding a bloodcurdling -16.94% in a week last week, ArQule closed this week at $8.39 and boosted a wonderful 5.27%.

ARQL marked an uptrend of rising tops and rising bottoms. Since its last top early July at $12.22, price slid and bounced up back from $7.52. Breaking down under $7.52 would cancel the current uptrend and it might test lower supports. Note that $12.22 might act as a resistance line. By mid May, SMA20w and SMA40w crossed up triggering a rise of 30.69%. Since early March when ARQL stock price broke up the SMA40w line, it gained $4.83 (135.67%).

ARQL stock chart (weekly)

ArQule stock price history

ArQule stock went public on October 16th, 1996 with a price of $12.251. Since then, ARQL stock lost a -31.50%, with a yearly average of -1.40%.

1: Adjusted price after possible price splits or reverse-splits.

ArQule stock historical price chart

ARQL stock reached 52-week highs on July at $12.22, and all-time highs 2000-02-17 with a price of 40.38.

ArQule stock price target is $12.00

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' ARQL stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we found 4 price targets for ArQule stock:
ARQL stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-9-16HC WainwrightInitiatesn/a$13.00-
2019-6-19Royal Bank of CanadaRaises Targetn/a$12.00-
2019-6-14Roth CapitalRaises Targetn/a$13.00-
2019-5-2Royal Bank of CanadaSet Price Targetn/a$10.00-
(in average)$0.00$12.000.0%
The price forecast for ArQule stock is $12.00, moving in a range between $13.00 and $10.00. In average, analysts' outlook on ARQL price target is stable from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On March, ArQule reported its latest financial data, close to analysts' consensus and posted a $-0.08 Earnings per Share. As soon as we get its posted EPS from the earnings report, we will update this report.
ARQL earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q2-n/a-0.1n/a
2017-Q32017-11-09-0.11-0.09n/a
2017-Q42018-03-05-0.09-0.09n/a
2018-Q12018-05-07-0.06-0.07n/a
2018-Q22018-08-010.020.05150.0%
2018-Q32018-10-31-0.06-0.05n/a
2018-Q42019-03-07-0.08-0.08n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a
2019-Q3-n/an/an/a

Annual financial results

Compared to 2016, last anual revenues report draw a dazzling gain of 447.12% to $25.76 million dollars. When comparing 2018 vs 2016, in line, profit margin (that is, the net income divided by revenues) rocketed a 422.35% to -60.09%.

ARQL annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$16 M-$-24.60 M-154.6%-
2014$11 M-29.26%$-23.39 M-207.8%-4.91%
2015$11 M-0.13%$-13.77 M-122.6%-41.11%
2016$4.71 M-58.10%$-22.72 M-482.4%64.93%
2018$26 M447.12%$-15.48 M-60.1%-31.85%

Quarterly financial results

ArQule reported $2.94 M in revenues for 2018-Q4, a -40.93% decline compared to previous quarter. Reported quarter earnings marked $-8.49 M with a profit margin of -288.58%. Profit margin plummed a -175.72% compared to previous quarter when profit margin was -112.85%. When comparing sales to same quarter last year, ArQule sales marked an exceptional increase and boosted a inf%. Looking back to recent quarterly results, ArQule posted 2 positive quarters in a row.
ARQL quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2018-Q1$4 M-$-6.53 M-157.9%-
2018-Q2$14 M231.22%$5.16 M37.6%-178.93%
2018-Q3$5 M-63.67%$-5.62 M-112.9%-208.98%
2018-Q4$3 M-40.93%$-8.49 M-288.6%51.04%
2019-Q1$1 M-54.27%$-10.27 M-763.3%20.97%

ArQule ownership

When you are planning to buy a company, it's always worth to have a look its ownership structure.

ArQule shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 1.74% of all shares.

Bearish positions for ARQL stock account 0.00%, no big difference from last month.

For a better context understanding, the following table shows ownership data compared to other related companies:

ARQLAMGNAVEOCYTKEXEL
Market cap$1.0 B$118.1 B$157.5 M$772.8 M$5.9 B
Total shares120.3 M599.7 M160.7 M58.7 M302.9 M
Float shares93.2 M598.3 M134.8 M46.4 M293.1 M
  - Institutional holdings (%)81.2%81.9%32.5%75.2%77.2%
  - Insider holdings (%)1.7%0.2%0.3%7.3%3.4%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

ArQule summary

Friday, September 20th, 2019
Open$7.98
Close$8.39
Day range$7.98 - $8.53
Previous close$8.02
Session gain4.61%
Average true range$0.55
50d mov avg$9.33
100d mov avg$8.74
200d mov avg$6.43
Daily patternlb01a
Weekly pattern lb03a

ArQule performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We selected Amgen, AVEO Pharmaceuticals, Cytokinetics, Exelixis, Infinity Pharmaceuticals and Eli Lilly and as the bechmarking frame for ArQule stock.
Stock3m6m12m
ARQLArQule-20.02%74.07%65.16%
AMGNAmgen6.00%7.15%-1.03%
AVEOAVEO Pharmaceutic...28.95%68.97%-65.73%
CYTKCytokinetics17.59%50.51%54.94%
EXELExelixis-8.47%-15.76%16.71%
INFIInfinity Pharmace...-27.50%-34.09%-51.67%
LLYEli Lilly and1.14%-8.44%11.63%

ArQule competitors

We picked a few stocks to conform a list of ArQule competitors to review if you are interested in investing in ARQL: